Follow us on Facebook!
Follow us on Twitter!
Follow us on Youtube!

Find below the preliminary agenda for the MPE Annual General Meeting 2019. Speakers will be confirmed soon and some topics are subject to change. You can also download the preliminary agenda here.


Friday, 15 March 2019

13:00 – 15:00

Check-in and registration/lunch 

15:00 – 15:10

Welcome & Introductions
Hans Scheurer – President MPE
Ananda Plate – CEO MPE
15:10 – 16.10 Myeloma Treatment Updates 

  • Treatment of newly diagnosed myeloma
  • Role of maintenance treatment
  • New and upcoming treatments for NDMM
  • Updates on treatment of relapsed myeloma
  • New and upcoming treatments for relapsed MM
  • Update on related conditions (myeloma, AL amyloidosis etc)

Speaker: Prof. Heinz Ludwig, Wilhelminen Cancer Research Institute, Austria tbc

16:10 – 17:00 Spotlight on MPE scholarship programme
Chair: Kate Morgan, MPE & Ana Vallejo, MPE

5-Minute presentations from 5 MPE members
17:00 – 17:15 Coffee break
17:15 – 19:00 Plenary Workshop AL Amyloidosis
Chair: Ananda Plate and Hans Scheurer, MPEIntroduction to AL amyloidosis (20 min)
Speaker: Dr Moshe Gatt, Israel
AL amyloidosis from a patient advocates view (10 min.)
Speaker: Daniel Drimer, Amyloidosis Israel Challenges of diagnosing myeloma from the patient advocates view (10 min.)
Speaker: Kate Morgan, Myeloma UK and Varda Shoham, Myeloma Israel (TBC)

Workshop (40 min. team work in small groups and 20 min.

  • How can the AL amyloidosis and myeloma community collaborate
    to help build a stronger AL amyloidosis community in Europe?
  • What does the picture of diagnosing AL amyloidosis and myeloma
    look like in your country?
  • How can we tackle the issue of late diagnosis of AL amyloidosis and
    myeloma at national level?
  • What can MPE do to tackle the issue of late diagnosis of AL amyloidosis and
    myeloma at a Europe level?
20:00 – 22:00 Dinner (Hotel restaurant)


Saturday, 16 March 2019
9:00 – 10:00 The role of CAR-T – Room: Sapporo/Harrare

  •  What is CAR-T?
  • How does it work?
  • How is it being looked at in myeloma?
  • Companies involved in this
  • Application in AL amyloidosis?
  • Regulatory challenges faced (e.g. cost, hospital provision etc)
  • Role of advocacy in trying to make this available for patients

Speaker: Dr. Michael Hudecek, University of Wuerzburg, Germany

10:00 – 10:15 Coffee break
10:15 – 11:15 AL amyloidosis clinical session – Updates in treatment of AL amyloidosis

  • Diagnostics
  • Link between myeloma and AL amyloidosis
  • Treatment of newly diagnosed AL amyloidosis (and updates from ASH)
  • Treatment of relapse AL amyloidosis (and updates from ASH)
  • Coordinated care in AL amyloidosis
  • Upcoming treatments and clinical trials

Speaker: Dr Moshe Gatt, Israel

Myeloma clinical session
Treatment challenges in myeloma

  • Riskstratification: High-risk vs. intermediate/low risk
  • Treating frailer, elderly patients
  • Treating younger patients with myeloma
  • Personalised forms of medicine

Speaker: Heinz Ludwig, AT tbc

11:15 – 11:30  Coffee break
11:30 – 12:30 Breakout Session Advocacy
“Surrogate end-points and biomarkers in myeloma and AL amyloidosis”

  •  Minimal residual disease in myeloma and AL amyloidosis
  • Biomarkers in myeloma and AL amyloidosis
  • Regulatory challenges associated with these and getting new medicines approved

 Speaker: Dr. Moshe Gatt, Israel

Breakout Session Advocacy
“Measuring and utilising quality of life”

  •  PROMS, PREMS, PRO, QoL measures and patient
  • Preference studies
  • Examples in myeloma
  • Examples in AL amyloidosis
  • How they can be used in practice?
  • Can they improve survival?

 Speaker: Jayne Gallinsky and Kate Morgan, Myeloma UK

12:30 – 14:00  Lunch
(45 minutes each – Choose 2 out of 3, 15 min for rotation)

  1. Internal and external communication with patients and stakeholders
    Speaker: Ana Vallejo, Myeloma Patients Europe
  2. Fundraising for patient groups
    Speaker: TBD
  3. Compliance and legal agreements (WECAN legal framework)
    Speaker: Ananda Plate, MPE/Jan Geissler, CML Advocates Network
16:15 – 16:45 Coffee Break
16:45 – 17:30 Supportive and psychosocial issues for myeloma and AL amyloidosis
Chair: Ibolya Keri, MOHA, Hungary (TBC)

  • Psychosocial issues for patients (supportive care, emotional care etc)
    Speaker: Fatima Castaño, psycho-oncologist
  • Communicating with patients
    Speaker: Diego Villalón, social worker, Fundación MÁS QUE IDEAS
19:30 – 22:00 Offsite dinner in Munich


Sunday, 17 March
8:30 – 10:45 General Assembly (for MPE members only)
11:15 – 11:45 Coffee break
11:45 – 13:00 General Assembly (for MPE members only)
13:00 – 14:00 Farewell lunch

For questions, please contact the MPE AGM team at

AGM Video gallery
Web links